Curocell (XKRX:372320) Debt-to-Revenue : N/A (As of Jun. 2023)

Curocell Debt-to-Revenue Chart

Competitive Comparison of Curocell's Debt-to-Revenue

For the Biotechnology subindustry, Curocell's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Curocell's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Curocell's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Curocell's Debt-to-Revenue falls into.

Curocell Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Curocell's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Curocell's annualized Debt-to-Revenue for the quarter that ended in Jun. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is two times the quarterly (Jun. 2023) Revenue data.

Curocell Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Curocell's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Curocell (XKRX:372320) Business Description